Condition: OligoProgressive Metastatic Disease · Hepatocellular Carcinoma (HCC) · Radiotherapy · Sponsor: Shandong Cancer Hospital and Institute
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Jinbo Yue, Doctor · 0531-67626442 · jbyue@sdfmu.edu.cn
Jinbo Yue, Doctor · jbyue@sdfmu.edu.cn
Always discuss trial participation with your own doctor first.
| Jinan, Shandong 0531 | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06841172